科创板上市公司独立董事 候选人声明与承诺 本人刘志常，已充分了解并同意由提名人上海毕得医药科技 股份有限公司董事会提名为上海毕得医药科技股份有限公司第 二届董事会独立董事候选人。本人公开声明，本人具备独立董事 任职资格，保证不存在任何影响本人担任上海毕得医药科技股份 有限公司独立董事独立性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行 政法规、部门规章及其他规范性文件，具有五年以上法律、经济 会计、财务、管理等履行独立董事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及 公司规章的要求： （一）《中华人民共和国公司法》等关于董事任职资格的规 定； （二）《中华人民共和国公务员法》关于公务员兼任职务的 规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》和上海证 券交易所自律监管规则有关独立董事任职资格和条件的相关规 定； （四）中共中央纪委、中共中央组织部《关于规范中管干部 辞去公职或者退（离）休后担任上市公司、基金管理公司独立董 事、独立监事的通知》的规定（如适用）； （五）中共中央组织部《关于进一步规范党政领导干部在企 业兼职（任职 ...

海通证券股份有限公司 关于上海毕得医药科技股份有限公司 首次公开发行部分限售股及战略配售限售股上市流通的核 查意见 海通证券股份有限公司（以下简称"海通证券"或"保荐机构"）作为上海 毕得医药科技股份有限公司（以下简称"毕得医药"或"公司"）首次公开发行 股票并在科创板上市持续督导期间的保荐机构，根据《证券发行上市保荐业务管 理办法》《上海证券交易所科创板股票上市规则》等有关法律法规和规范性文件 的要求，对毕得医药首次公开发行部分限售股及战略配售限售股上市流通的事项 进行了核查，具体情况如下： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2022 年 8 月 19 日出具的《关于同意上海毕 得医药科技股份有限公司首次公开发行股票注册的批复》（证监许可[2022]1885 号），公司获准首次向社会公开发行人民币普通股（A 股）16,229,100 股,并于 2022 年 10 月 11 日在上海证券交易所科创板上市。公司首次公开发行 A 股股票 后总股本为 64,916,392 股，其中无限售条件流通股 13,348,796 股，占公司总股本 的 20.56%；有限售条件流通股为 51,567, ...

证券代码：688073 证券简称：毕得医药 公告编号：2023-031 上海毕得医药科技股份有限公司 首次公开发行部分限售股及战略配售限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性依法承担法律责任。 重要内容提示： 本次上市流通的战略配售股份数量为 2,272,074 股，限售 期为自上海毕得医药科技股份有限公司（以下简称"公司"或"毕 得医药"）首次公开发行上市之日起 12 个月。本公司确认，上市 流通数量为该限售期的全部战略配售股份数量。 除战略配售股份外，本次上市流通的限售股数量为 15,351,223 股。 本次限售股上市流通日期为 2023 年 10 月 11 日。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2022 年 8 月 19 日出具的 《关于同意上海毕得医药科技股份有限公司首次公开发行股票 注册的批复》（证监许可[2022]1885 号），公司获准首次向社 会公开发行人民币普通股（A 股）16,229,100 股,并于 2022 年 1 10 月 11 日在上海证券交易所科创板上市 ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2023, representing a 20% increase compared to the same period last year[1]. - The company's operating revenue for the first half of 2023 reached ¥522.63 million, representing a 41.76% increase compared to ¥368.67 million in the same period last year[26]. - The net profit attributable to shareholders for the first half of 2023 was ¥83.81 million, up 41.63% from ¥59.18 million in the previous year[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 56.51%, amounting to ¥91.87 million compared to ¥58.70 million in the same period last year[26]. - The company achieved a main business revenue of 522.59 million yuan, a year-on-year increase of 41.75%[27]. - Basic earnings per share increased by 41.54% to 0.92 yuan, while diluted earnings per share also rose by the same percentage[27]. - The net cash flow from operating activities for the first half of 2023 was -¥45.24 million, a significant decrease from ¥7.29 million in the previous year, reflecting a 720.73% decline[26]. - The company has no plans for profit distribution or capital increase during this reporting period[1]. User Growth and Market Expansion - User data indicates a growth in active users by 15%, reaching a total of 1.2 million users by June 30, 2023[1]. - The company is expanding its market presence in Southeast Asia, targeting a 25% increase in market share by the end of 2024[1]. - The company is actively implementing marketing strategies to increase brand awareness and expand its business footprint in emerging markets[38]. - The company has established partnerships with 90% of the top 20 global pharmaceutical companies, showcasing its technological advantages in boron and fluorine-containing products[40]. Research and Development - New product development includes the launch of two innovative drug candidates, expected to enter clinical trials by Q4 2023[1]. - Research and development (R&D) investment increased by 45.02% year-on-year, totaling approximately ¥26.78 million, primarily due to a 57.37% rise in employee compensation[46][47]. - The total number of authorized intellectual property projects reached 93, including 33 invention patents and 15 utility model patents[44]. - The company has developed over 20 self-researched fluorine reagents, applicable to more than 1,000 trifluoromethylation molecular blocks[41]. - The R&D department is focusing on enhancing the quality of its boron-containing molecular block library, with ongoing updates to existing products[40]. - The company is focusing on the development of boronic acid and fluorine-containing building block product lines to support clients in new drug research[39]. - The company is committed to advancing its research in the field of agricultural chemicals and pharmaceuticals, targeting innovative solutions[53]. Financial Risks and Challenges - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[1]. - The gross profit margin has been declining due to strategic price adjustments to align with market competitors[87]. - Inventory impairment losses have increased, impacting operating cash flow and raising financial risks[87]. - Foreign exchange risks are heightened due to a high proportion of exports, which could affect competitiveness and lead to exchange losses[87]. - The company faces risks related to talent retention, product quality control, and management scalability as it continues to expand its business operations[85]. Shareholder Commitments and Regulations - The company emphasizes compliance with the regulations set by the China Securities Regulatory Commission and the Shanghai Stock Exchange regarding shareholding commitments[131]. - The company commits to a 36-month lock-up period for shares held before the IPO, with an automatic extension of at least 6 months if the stock price falls below the IPO price for 20 consecutive trading days within the first 6 months post-IPO[132]. - The company will ensure that any profit distribution does not exceed the cumulative distributable profit and does not harm its ongoing operational capability[177]. - The controlling shareholders have pledged to take necessary measures to ensure compliance with the profit distribution policy and dividend return plan[182]. - The company will strictly adhere to the regulations set by the China Securities Regulatory Commission and the Shanghai Stock Exchange regarding shareholding lock-up periods[136]. Future Outlook and Strategic Initiatives - The company has identified potential areas for mergers and acquisitions to enhance its market position[200]. - Future outlook remains positive, with ongoing evaluations of new technologies and market opportunities[200]. - The company is committed to expanding its market presence through strategic research and development initiatives in advanced materials and pharmaceuticals[70]. - The company plans to expand its market presence through new product development and strategic investments[200].

上海毕得医药科技股份有限公司（以下简称"公司"）于2023 年7月10日召开第一届董事会第十八次会议，审议通过了《关于 变更公司注册资本、经营范围及修订<公司章程>并办理工商变更 登记的议案》。为满足经营发展需要，公司拟对经营范围进行变 更，同时因实施2022年度利润分配方案，公司注册资本变更，因 此公司相应修订了公司章程。具体情况详见公司于2023年7月11 日在上海证券交易所网站（www.sse.com.cn）披露的《上海毕得 医药科技股份有限公司关于变更公司注册资本、经营范围及修订 <公司章程>并办理工商变更登记的公告》（公告编号：2023-019）。 2023年7月26日，本事项经公司2023年第一次临时股东大会审议 通过。 由于市场监督管理局对经营范围登记规范化工作的要求，公 司按照规范条目将经营范围进行了调整，经核准登记的经营范围 与2023年第一次临时股东大会审议通过的无实质性变化。 公司已完成工商变更登记和备案手续，并于近期取得了由上 关于完成工商变更并取得营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担 ...

标题：关于上海毕得医药科技股份有限公司有关事项的监管工作函 证券代码：688073 证券简称：毕得医药 监管类型：监管工作函 涉及对象：上市公司,董事,监事,高级管理人员,控股股东及实际控制人,中介机构及其相关 人员 处分日期：2023-08-10 处理事由：关于上海毕得医药科技股份有限公司董事会秘书离职相关事项的监管工作函 ...

上海毕得医药科技股份有限公司 证券代码：688073 证券简称：毕得医药 公告编号：2023-025 票上市规则》《上市公司股东、董监高减持股份的若干规定》《上 海证券交易所上市公司股东及董事、监事、高级管理人员减持股 份实施细则》等相关规定，并继续遵守其作为高级管理人员在公 司首发上市时做出的相关承诺。 李涛先生在担任公司副总经理、董事会秘书期间，恪尽职守、 勤勉尽责，公司及董事会对李涛先生在任职期间为公司发展所作 出的突出贡献表示衷心感谢！ 特此公告。 关于公司副总经理、董事会秘书辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 上海毕得医药科技股份有限公司（以下简称"公司"）董事 会于近日收到公司副总经理、董事会秘书李涛先生的辞职报告， 李涛先生因个人原因申请辞去公司副总经理、董事会秘书职务， 辞任后不再担任公司任何职务。根据《公司法》《上海证券交易 所科创板股票上市规则》等法律法规以及《公司章程》的规定， 李涛先生的辞职申请自送达公司董事会之日起生效。 李涛先生已完成相关工作和档案文件的交接，其辞职不会对 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥252,455,900.29, representing a year-on-year increase of 42.58%[5] - The net profit attributable to shareholders for Q1 2023 was ¥36,928,240.19, reflecting a growth of 45.22% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥38,966,750.90, which is an increase of 54.64% year-on-year[5] - Total revenue for Q1 2023 reached ¥252,455,900.29, a significant increase of 42.5% compared to ¥177,067,881.79 in Q1 2022[19] - Operating profit for Q1 2023 was ¥43,644,938.15, up 44.9% from ¥30,115,844.41 in the same period last year[20] - Net profit for Q1 2023 amounted to ¥36,928,240.19, representing a 45.4% increase from ¥25,428,402.43 in Q1 2022[20] - Basic and diluted earnings per share for Q1 2023 were both ¥0.57, an increase of 9.62% year-on-year[6] - Basic and diluted earnings per share for Q1 2023 were both ¥0.57, compared to ¥0.52 in Q1 2022, marking a 9.6% increase[21] Research and Development - The total R&D investment for Q1 2023 was ¥16,163,087.87, marking a significant increase of 66.05% compared to the previous year[6] - The R&D investment accounted for 6.40% of operating revenue, up by 0.90 percentage points from the previous year[6] - Research and development expenses for Q1 2023 were ¥16,163,087.87, a 66.1% increase from ¥9,733,638.06 in Q1 2022[20] Assets and Liabilities - The total assets at the end of Q1 2023 were ¥2,425,420,936.29, which is a 2.81% increase from the end of the previous year[6] - Total assets increased from CNY 2,359,206,247.92 to CNY 2,425,420,936.29, representing a growth of approximately 2.8%[17] - Total current assets increased from CNY 2,244,601,787.13 to CNY 2,309,998,099.82, reflecting a growth of approximately 2.9%[16] - Current liabilities increased from CNY 249,070,839.56 to CNY 286,230,254.30, showing a rise of about 15%[17] - Non-current liabilities decreased from CNY 31,208,972.64 to CNY 28,539,034.51, reflecting a decline of approximately 8.6%[17] - The company’s total liabilities increased from CNY 280,279,812.20 to CNY 314,769,288.81, indicating a growth of about 12.3%[17] - Total liabilities increased to ¥317,437,607.11 in Q1 2023, compared to ¥283,052,077.86 in Q1 2022, reflecting a growth of 12.1%[18] - The equity attributable to shareholders at the end of Q1 2023 was ¥2,107,983,329.18, reflecting a 1.53% increase compared to the end of the previous year[6] - Total equity rose to ¥2,107,983,329.18 in Q1 2023, up from ¥2,076,154,170.06 in Q1 2022, indicating a growth of 1.5%[18] Cash Flow - The net cash flow from operating activities for Q1 2023 was -¥21,457,616.26, indicating a decrease of 67.02% year-on-year[6] - In Q1 2023, the cash inflow from operating activities totaled $274,832,209.08, compared to $166,550,481.91 in Q1 2022, representing an increase of approximately 64.9%[24] - The cash outflow from operating activities was $296,289,825.34, up from $231,606,316.14 in the previous year, indicating a rise of about 28%[24] - The net cash flow from operating activities was -$21,457,616.26, an improvement from -$65,055,834.23 in Q1 2022[24] - Cash inflow from investment activities was $3,473,049.81, while cash outflow was $10,475,799.19, resulting in a net cash flow of -$7,002,749.38 for investment activities[25] - The cash inflow from financing activities was $194,243.33, compared to $55,099.20 in Q1 2022, showing an increase of approximately 252%[25] - The net cash flow from financing activities was -$3,045,407.93, slightly improved from -$3,633,084.89 in the same quarter last year[25] - The total cash and cash equivalents at the end of Q1 2023 stood at $1,463,790,926.46, down from $1,495,462,681.26 at the beginning of the quarter[25] Market and Future Outlook - The company experienced strong demand in the drug molecular block and scientific reagent segments, contributing to the overall revenue growth[9] - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[15] Other Financial Metrics - The company reported a significant increase in accounts receivable from CNY 177,028,268.89 to CNY 219,428,069.98, which is an increase of about 23.9%[16] - Inventory rose from CNY 521,860,490.24 to CNY 574,843,179.86, indicating an increase of about 10.1%[16] - Cash and cash equivalents rose from CNY 1,470,945,899.08 to CNY 1,505,956,232.01, marking an increase of approximately 2.4%[16] - The company reported a total operating cost of ¥203,401,460.75 in Q1 2023, which is an increase of 43.9% from ¥141,216,584.11 in Q1 2022[19] - Other comprehensive income for Q1 2023 showed a loss of ¥14,098,118.88, compared to a loss of ¥80,104.28 in Q1 2022[21] - Employee compensation payments increased to $35,142,187.82 from $33,097,076.01, reflecting a rise of about 6.2%[24] - The company experienced a negative impact of -$165,981.23 from exchange rate fluctuations on cash and cash equivalents[25]

Financial Performance - The company achieved a net profit attributable to shareholders of RMB 145,970,727.07, with the parent company reporting a net profit of RMB 93,801,072.91[5]. - The proposed cash dividend is RMB 15.40 per 10 shares (including tax), totaling RMB 99,971,243.68, which represents 68.49% of the annual net profit attributable to shareholders[5]. - The company's operating revenue for 2022 was CNY 833.83 million, representing a 37.55% increase compared to CNY 606.22 million in 2021[26]. - The net profit attributable to shareholders for 2022 was CNY 145.97 million, a 49.60% increase from CNY 97.57 million in 2021[26]. - The basic earnings per share for 2022 was CNY 2.77, up 35.78% from CNY 2.04 in 2021[27]. - The total assets at the end of 2022 were CNY 2.36 billion, a 160.36% increase from CNY 906.13 million at the end of 2021[26]. - The company's R&D expenditure as a percentage of operating revenue was 5.53% in 2022, slightly down from 5.75% in 2021[27]. - The cash flow from operating activities for 2022 was CNY 29.87 million, a significant recovery from a negative cash flow of CNY 64.88 million in 2021[26]. - The weighted average return on equity for 2022 was 14.24%, down from 18.15% in 2021, indicating a decrease of 3.91 percentage points[27]. - The net assets attributable to shareholders increased to CNY 2.08 billion at the end of 2022, a 230.15% increase from CNY 628.86 million at the end of 2021[26]. Research and Development - The company provided comprehensive drug research and development services for global pharmaceutical companies and biopharmaceutical research institutions[14]. - The company focuses on the discovery, development, and commercialization of innovative molecular targeted immunotherapy drugs for cancer treatment[14]. - The company emphasizes the importance of drug molecular building blocks in designing and synthesizing candidate active drug molecules[14]. - The company is engaged in the research and development of new drugs, including the discovery of drug targets and the screening of lead compounds[15]. - The company aims to optimize lead compounds to meet safety and efficacy requirements for new drug development[15]. - The company is involved in preclinical research, which includes chemical synthesis and pharmacological studies[15]. - The company highlights the significance of drug targets in modern new drug development[15]. - The company is committed to developing innovative drugs with independent intellectual property rights[15]. - The company has the capability to provide over 400,000 novel and diverse drug molecular blocks, with a stock of over 86,000 types readily available[37]. - The R&D team expanded to 168 members, with R&D expenses amounting to 46.07 million yuan, reflecting a 32.08% increase year-on-year[40]. Market Expansion and Strategy - The company aims to continue expanding its market presence and investing in new product development to drive future growth[19]. - The company aims to become a leading enterprise in the global molecular block field, actively expanding its presence in the U.S., Europe, and India[43]. - The company plans to enhance inventory management efficiency and expand its global business scale to support new drug development[28]. - The company is exploring partnerships with international firms to enhance its global footprint and leverage new technologies[146]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 100 million allocated for potential deals[148]. - The company plans to develop high-quality serum products as a breakthrough in the life sciences and biopharmaceutical fields[122]. - The company is focusing on the independent research and development of boron-containing drug molecular building blocks, aiming to enhance brand awareness and open overseas markets[129]. Corporate Governance - The board of directors and senior management have confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company has not disclosed any special arrangements for corporate governance[8]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective operation of the shareholders' meeting, board of directors, and supervisory board[179]. - The company adheres to strict information disclosure obligations, ensuring timely and accurate communication with investors[135]. - The company held two shareholder meetings in 2022, ensuring compliance with legal procedures and allowing all shareholders to exercise their voting rights[134]. - The company has not reported any changes in shareholding for key executives during the reporting period[140]. - The company has maintained a stable leadership team with no new appointments or departures reported during the year[140]. Environmental and Social Responsibility - The company emphasizes the importance of ESG (Environmental, Social, and Governance) management, integrating it into overall strategy and operations[183]. - The company invested ¥2.1525 million in environmental protection during the reporting period[184]. - The company has established an environmental management system compliant with ISO14001:2015 standards[190]. - The company is not classified as a key pollutant discharge unit and operates in the "M73 Research and Experimental Development" industry, which is not heavily polluting[185]. - There were no administrative penalties received due to environmental issues during the reporting period[186]. Risks and Challenges - The company has outlined various risks and countermeasures in its report, emphasizing the importance of investor awareness regarding investment risks[4]. - The company faces risks related to talent retention and product quality control, which could impact future performance[84][86].

证券代码：688073 证券简称：毕得医药 公告编号：2023-006 上海毕得医药科技股份有限公司 关于召开 2022 年度业绩说明会的公告 一、 说明会类型 会议召开时间：2023 年 04 月 25 日(星期二) 下午 13:00-14:00 会议召开地点：上海证券交易所上证路演中心（网址： 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 18 日(星期二) 至 04 月 24 日(星期 一)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 ir@bidepharmatech.com 进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度 的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在 信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2023 年 04 月 25 日 下午 13:00-14:00 （二） 会议召开地点：上证路演中心 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏， ...